Abstract
The first indication of BoNT utility in urology was actually not for the overactive bladder but rather injection into the urethral sphincter in spinal cord injured patients to treat detrusor-sphincter dyssynergia (DSD) (Dykstra et al. 1988). In this chapter, we will focus on BoNT injection into the urethral sphincter and pelvic floor for patients with neurogenic detrusor-sphincter dyssynergia, non-neurogenic sphincter discoordination such as dysfunctional voiding or shy bladder syndrome, and pelvic floor spasticity and pain. Because the number of patients who may be candidates for sphincter or pelvic floor injection are small, and etiology and diagnoses diverse, there are no current registry trials to seek regulatory approval for sphincter BoNT application in most developed countries. Therefore, clinicians should be aware that sphincter BoNT injections are off-label applications of BoNT.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abbott J (2009) The use of botulinum toxin in the pelvic floor for women with chronic pelvic pain-a new answer to old problems? J Minim Invasive Gynecol 16:130–135
Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG (2006) Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 108:915–923
Chen YH, Kuo HC (2004) Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol Int 73:156–161; discussion 161–162
Chen SL, Bih LI, Chen GD, Huang YH, You YH, Lew HL (2010) Transrectal ultrasound-guided transperineal botulinum toxin a injection to the external urethral sphincter for treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury. Arch Phys Med Rehabil 91:340–344
de Seze M, Petit H, Gallien P, de Seze MP, Joseph PA, Mazaux JM, Barat M (2002) Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42:56–62
Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:919–922
FitzGerald MP, Brubaker L (2001) The etiology of urinary retention after surgery for genuine stress incontinence. Neurourol Urodyn 20:13–21
Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze M, Bellissant E (2005) Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 76:1670–1676
Ghazizadeh S, Nikzad M (2004) Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 104:922–925
Gunter J, Brewer A, Tawfik O (2004) Botulinum toxin a for vulvodynia: a case report. J Pain 5:238–240
Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG (2004) Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 44:46–50
Kuo HC (2005) Effectiveness of urethral injection of botulinum A toxin in the treatment of voiding dysfunction after radical hysterectomy. Urol Int 75:247–251
Kuo HC (2007) Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology 69:57–61; discussion 61–62
Kuo HC (2008) Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn 27:793–796
Lim SK, Quek PL (2008) Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study. Eur Urol 53:620–625
Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165:1107–1110
Romito S, Bottanelli M, Pellegrini M, Vicentini S, Rizzuto N, Bertolasi L (2004) Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest 58:164–167
Smith CP, O’Leary M, Erickson J, Somogyi GT, Chancellor MB (2002) Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct 13:185–186
Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65:37–41
Zermann D, Ishigooka M, Schubert J, Schmidt RA (2000) Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 38:393–399
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Chancellor, M.B., Smith, C.P. (2011). Sphincter and Pelvic Floor Disorders Applications. In: Botulinum Toxin in Urology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-03580-7_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-03580-7_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-03579-1
Online ISBN: 978-3-642-03580-7
eBook Packages: MedicineMedicine (R0)